Press Releases

WESTBURY, NY - May 31, 2018 - BioIVT, a leading provider of biospecimens and related services, today announced that the Human Tissue Authority (HTA) has granted a satellite license to its West Sussex facility.

“Our goal is to always provide our customers with the highest quality biospecimens and the best possible customer service. Now that our West Sussex site is covered by our UK HTA license, its biomaterial storage is also certified to meet HTA standards, and we can use that facility for more convenient onward shipping for our customers,” said Kelly Sapsford, BioIVT general manager, Europe, Middle East and Africa operations. 

Clients purchasing human biospecimens, including tissues, biofluids and primary cell products, from BioIVT’s HTA-licensed sites are assured that donors receive accurate information and are fully  informed prior to giving their consent; donor samples are collected and handled according to required storage, use, and disposal protocols; and collection sites undergo regular audits to verify their adherence to approved standard operating procedures.

“After BioIVT’s acquisition of Asterand Bioscience in August 2017, I worked closely with the extended team to secure HTA certification for our West Sussex site to enable them to store human biomaterials prior to distribution to our research clients,” said Amanda J. Woodrooffe, PhD, BioIVT vice president and general manager, Royston operations and HTA corporate license holder. “Our Royston UK facility has been HTA licensed since August 2007.”

The HTA was created by the UK Parliament in 2005 as a non-departmental public body of the Department of Health. HTA ensures that human tissue is used safely and ethically, and with proper consent. It regulates organizations that remove, store and use tissue for research and medical treatment. It also approves organ and bone marrow donations from living people.

About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease-state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.